虚血性心疾患(突然死を含む)の発生率と致命率の推移と発症要因に関する研究

「目的」新潟市と長岡市において、急性心筋梗塞と突然死の新発生例を出来るだけ悉皆的に登録するシステムを構築することにより、両疾患の発生率、死亡率を求め、併せて両疾患の発症要因を知ることにある。「方法」15-65歳の両市内の在住者から急性心筋梗塞と突然死が発生する度に、医療機関から発生通知を受け、病院に赴きカルテ調査を行った。一方、死亡症例の登録状況を確認するため、両市の全ての死亡小票を閲覧して対比した。発症要因に関する調査に同意の得られた症例本人または家族に対して、日常生活等に関する聞き取り調査を電話で行った。発症要因を探るための対照群として新潟市内の某ドック受診者544名を設定し、症例群と同様の方法で聞き取り調査を行った。「結果と考察」1年間で登録された急性心筋梗塞は70例(生存67例、死亡3例)、突然死は83例であった。死亡小票からあがった症例数は各々3 例と154例であった。登録された突然死中の急性心筋梗塞者割合(75%)から、死亡小票上の突然死に占める急性心筋梗塞数を推定し、その年間推定発生率を求めた結果、人口10万人当たり17.1人(45-65歳に限ると39.5人)であった。既往歴を両症例群で対照群と比較した結果、突然死群では循環器系疾患が、急性心筋梗塞では冠危険因子が高率であった。両群とも発症前1週間以内の自律神経症状(発汗異常、熱感・冷感など)が高率であった。突然死群は急性心筋梗塞群に比べて日常生活の仕事労作が大きく、死亡前1週間の睡眠時間の減少者が高率であった。短期的ストレスを訴えた率は急性心筋梗塞でのみ対照群との間に有意差が認められた。科学研究費補助金 研究種目:一般研究(B) 課題番号:06454236 研究代表者:豊嶋 英明 研究期間:1994-1995年度research repor

Observation of the ηc(2S) in Exclusive B→KKSK-π+ Decays

journal articl

Philippine English : a case of language drift

departmental bulletin pape

Concrete Durability Assessment for Scaling by Reliability Theory

application/pdfThe proper prediction of concrete deterioration is important for estimating and evaluating　the service life of concrete structures and for maintaining and managing them. It is necessary to establish the limit of deterioration in management (the deterioration limit) and understand the probability of exceeding that limit. In this study， the introduction of reliability theory to predict and evaluate concrete deterioration was tried in order to determine if it could be used for these purposes, predicting surface scaling, which is a typical form of surface deterioration of concrete structures located in cold regions and an important factor in the maintenance of the beauty of value-added concrete structures， and the deterioration of cover concrete of steel.departmental bulletin pape

Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer-1

<p><b>Copyright information:</b></p><p>Taken from "Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer"</p><p>http://www.biomedcentral.com/1471-2407/7/121</p><p>BMC Cancer 2007;7():121-121.</p><p>Published online 3 Jul 2007</p><p>PMCID:PMC1948004.</p><p></p>aCa-2, AsPc-1 and Capan-2 cells. The individual doses of gemcitabine and troxacitabine to achieve 90% (straight line) growth inhibition (Fa = 0.90), 75% (hyphenated line) growth inhibition (Fa = 0.75), and 50% (dotted line) growth inhibition (Fa = 0.50) were plotted on the x- and y-axes. Combination index (CI) values calculated using Calcusyn software is represented by points above (indicate antagonism between drugs) or below the lines (indicate synergy). (X symbol) ED(plus sign) EDand (open dotted circle ) ED

Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer-3

<p><b>Copyright information:</b></p><p>Taken from "Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer"</p><p>http://www.biomedcentral.com/1471-2407/7/121</p><p>BMC Cancer 2007;7():121-121.</p><p>Published online 3 Jul 2007</p><p>PMCID:PMC1948004.</p><p></p>xacitabine or gemcitabine either alone or in combination at a ratio of 1:100 of gemcitabine vs. troxacitabine, for 72 h, after which cells were harvested by trypsinization and their numbers determined using electronic particle counting. Each data point represents the mean ± SD of three determinations. Gemcitabine (open squares), troxacitabine (open inverted triangle), gemcitabine + troxacitabine (open circle). The GIvalues for exposures to troxacitabine and gemcitabine alone are given in Table 2

Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer-0

<p><b>Copyright information:</b></p><p>Taken from "Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer"</p><p>http://www.biomedcentral.com/1471-2407/7/121</p><p>BMC Cancer 2007;7():121-121.</p><p>Published online 3 Jul 2007</p><p>PMCID:PMC1948004.</p><p></p>xacitabine or gemcitabine either alone or in combination at a ratio of 1:100 of gemcitabine vs. troxacitabine, for 72 h, after which cells were harvested by trypsinization and their numbers determined using electronic particle counting. Each data point represents the mean ± SD of three determinations. Gemcitabine (open squares), troxacitabine (open inverted triangle), gemcitabine + troxacitabine (open circle). The GIvalues for exposures to troxacitabine and gemcitabine alone are given in Table 2

Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer-4

<p><b>Copyright information:</b></p><p>Taken from "Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer"</p><p>http://www.biomedcentral.com/1471-2407/7/121</p><p>BMC Cancer 2007;7():121-121.</p><p>Published online 3 Jul 2007</p><p>PMCID:PMC1948004.</p><p></p>aCa-2, AsPc-1 and Capan-2 cells. The individual doses of gemcitabine and troxacitabine to achieve 90% (straight line) growth inhibition (Fa = 0.90), 75% (hyphenated line) growth inhibition (Fa = 0.75), and 50% (dotted line) growth inhibition (Fa = 0.50) were plotted on the x- and y-axes. Combination index (CI) values calculated using Calcusyn software is represented by points above (indicate antagonism between drugs) or below the lines (indicate synergy). (X symbol) ED(plus sign) EDand (open dotted circle ) ED